| A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma | Mosunetuzumab | Phase 1 | Not yet recruiting | Weill Medical College of Cornell University | Nov 17, 2026 |
| A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma | Elranatamab | — | Not yet recruiting | Pfizer | Nov 9, 2026 |
| Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL | Blinatumomab | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Nov 6, 2026 |
| A Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation | Epcoritamab | Phase 2 | Recruiting | German CLL Study Group | Nov 5, 2026 |
| Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma | Glofitamab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | Nov 5, 2026 |
| Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Blinatumomab, Muromonab-CD3 | Phase 1 | Not yet recruiting | City of Hope Medical Center | Nov 3, 2026 |
| Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial | Mosunetuzumab, Muromonab-CD3 | Phase 2 | Not yet recruiting | University of Washington | Nov 2, 2026 |
| A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML | Muromonab-CD3 | Phase 1 | Not yet recruiting | Seattle Children's Hospital | Oct 29, 2026 |
| Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | Elranatamab | Phase 2 | Not yet recruiting | PETHEMA Foundation | Oct 28, 2026 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer | Tarlatamab | Phase 2 | Not yet recruiting | AbbVie | Oct 26, 2026 |
| RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab | Elranatamab | — | Not yet recruiting | The Royal Wolverhampton Hospitals NHS Trust | Oct 23, 2026 |
| Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma | Glofitamab | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | Oct 22, 2026 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma | Talquetamab, Teclistamab | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | Oct 22, 2026 |
| Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung Cancer | Tarlatamab | — | Active, not recruiting | Ruijin Hospital | Oct 21, 2026 |
| REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) | Muromonab-CD3, Odronextamab | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | Oct 21, 2026 |
| Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi) | Epcoritamab | Phase 2 | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | Oct 20, 2026 |
| Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas | Epcoritamab, Glofitamab | Phase 2 | Recruiting | National Research Center for Hematology, Russia | Oct 20, 2026 |
| A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments | Elranatamab | Phase 4 | Not yet recruiting | Pfizer | Oct 19, 2026 |
| BLinatumomab and iNKT in Relapsed B-Cell ALL | Blinatumomab | Phase 1 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | Oct 9, 2026 |
| A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections | Epcoritamab | — | Not yet recruiting | AbbVie | Oct 7, 2026 |
| Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment. | Epcoritamab | Phase 2 | Not yet recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | Oct 6, 2026 |
| Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome | Blinatumomab | Phase 2 | Not yet recruiting | Beijing Tongren Hospital | Oct 1, 2026 |
| Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL | Blinatumomab | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Sep 25, 2026 |
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI | Epcoritamab | Phase 2 | Not yet recruiting | University of California, Irvine | Sep 14, 2026 |
| Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy | Epcoritamab | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | Sep 10, 2026 |
| Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status | Tarlatamab | Phase 2 | Recruiting | AIO-Studien-gGmbH | Sep 4, 2026 |
| Teclistamab In Waldenstrom's Macroglobulinemia | Teclistamab | Phase 2 | Not yet recruiting | Massachusetts General Hospital | Aug 28, 2026 |
| Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma | Elranatamab | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Aug 27, 2026 |
| A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A | Elranatamab | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Aug 26, 2026 |
| Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas: A Phase II Proof-of-concept Study | Tarlatamab | Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | Aug 26, 2026 |
| Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study) | Tarlatamab | Phase 1 | Not yet recruiting | Vall d'Hebron Institute of Oncology | Aug 26, 2026 |
| Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma | Epcoritamab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | Aug 25, 2026 |
| Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) | Tarlatamab | Phase 3 | Recruiting | Amgen | Aug 21, 2026 |
| Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma | Glofitamab | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | Aug 19, 2026 |
| Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma. | Teclistamab | Phase 2 | Not yet recruiting | Odense University Hospital | Aug 11, 2026 |
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL | Glofitamab | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | Aug 6, 2026 |
| Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics | Glofitamab | Phase 2 | Not yet recruiting | Joshua Brody | Aug 5, 2026 |
| A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease | Talquetamab, Teclistamab | Phase 3 | Not yet recruiting | Polish Myeloma Consortium | Jul 31, 2026 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma | Teclistamab | Phase 3 | Recruiting | AbbVie | Jul 27, 2026 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma | Glofitamab, Muromonab-CD3 | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | Jul 24, 2026 |
| A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL | Blinatumomab | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Jul 23, 2026 |
| TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) | Talquetamab | Phase 1 | Not yet recruiting | Montefiore Medical Center | Jul 22, 2026 |
| AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL | Glofitamab | Phase 2 | Not yet recruiting | Ruijin Hospital | Jul 21, 2026 |
| Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation | Blinatumomab, Teclistamab | Early phase 1 | Not yet recruiting | West China Hospital | Jul 15, 2026 |
| A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC) | Tarlatamab | Phase 2 | Not yet recruiting | University of Cologne | Jul 13, 2026 |
| Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90% | Blinatumomab, Teclistamab | Phase 4 | Not yet recruiting | West China Hospital | Jul 8, 2026 |
| The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab | Foralumab, Muromonab-CD3 | Phase 2 | Enrolling by invitation | Tiziana Life Sciences LTD | Jul 7, 2026 |
| Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers | Muromonab-CD3 | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | Jul 7, 2026 |
| GMMG-HD11/DSMM XXI/64007957MMY3010 | Teclistamab | Phase 3 | Not yet recruiting | University of Heidelberg Medical Center | Jun 26, 2026 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma | Talquetamab, Muromonab-CD3 | Phase 2 | Recruiting | Naresh Bumma | Jun 18, 2026 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level | Talquetamab | Phase 3 | Recruiting | University of Leeds | Jun 16, 2026 |
| HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV | Elranatamab | Phase 1 | Recruiting | University of Illinois Chicago | Jun 15, 2026 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma | Elranatamab | Phase 2 | Recruiting | SCRI Development Innovations, LLC | Jun 10, 2026 |
| Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment | Mosunetuzumab | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | Jun 10, 2026 |
| Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer | Tarlatamab | Phase 3 | Not yet recruiting | PrECOG, LLC. | Jun 9, 2026 |
| A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | Mosunetuzumab | Phase 2 | Recruiting | Hoffmann-La Roche | May 20, 2026 |
| Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma | Talquetamab | Phase 1 | Recruiting | Christopher Strouse | May 12, 2026 |
| Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD | Mosunetuzumab | Phase 2 | Recruiting | M.D. Anderson Cancer Center | May 5, 2026 |
| Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma | Mosunetuzumab | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | Apr 29, 2026 |
| Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) | Mosunetuzumab | Phase 2 | Not yet recruiting | University of Utah | Apr 23, 2026 |
| Talquetamab in Patients With Refractory Generalized Myasthenia Gravis | Talquetamab | Not applicable | Not yet recruiting | First Affiliated Hospital of Chongqing Medical University | Mar 30, 2026 |
| BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. | Talquetamab | Phase 4 | Not yet recruiting | Anne Louise Tølbøll Sørensen | Mar 16, 2026 |
| Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP). | Mosunetuzumab | — | Recruiting | Andrés José Maria Ferreri | Dec 12, 2025 |
| Odronextamab in Low Tumor Volume Advanced FL | Odronextamab | Phase 2 | Recruiting | Gottfried von Keudell, MD PhD | Aug 19, 2025 |
| Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis | Odronextamab | Phase 1 | Recruiting | Regeneron Pharmaceuticals | May 16, 2025 |
| Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis | Foralumab | Phase 2 | Recruiting | Tiziana Life Sciences LTD | Mar 24, 2025 |
| A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) | Foralumab | Phase 2 | Recruiting | Tiziana Life Sciences LTD | Mar 11, 2025 |
| Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy | Odronextamab | Phase 2 | Recruiting | University of California, Davis | Mar 3, 2025 |
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T | Odronextamab | Phase 2 | Recruiting | University of Washington | Jan 20, 2025 |
| Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation | Odronextamab | Phase 1 | Recruiting | City of Hope Medical Center | Dec 16, 2024 |
| Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease | Foralumab | Phase 2 | Recruiting | Brigham and Women's Hospital | Jul 8, 2024 |
| A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma | Odronextamab | Phase 3 | Active, not recruiting | Regeneron Pharmaceuticals | Jan 30, 2024 |
| A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma | Odronextamab | Phase 3 | Recruiting | Regeneron Pharmaceuticals | Nov 28, 2023 |
| Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia | Flotetuzumab | Phase 1 | Active, not recruiting | Children's Oncology Group | Nov 12, 2019 |
| PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases | Foralumab | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | Jan 8, 2016 |